Review ties incretin hair loss to speed of weight loss, not drug toxicity

The wire

1. 01The Acta Diabetologica narrative review pooled trial, observational and pharmacovigilance data on hair loss with semaglutide, tirzepatide and retatrutide, naming female sex and over 10% weight reduction as the strongest predictors.
2. 02Tirzepatide showed stronger associations with shedding than older GLP-1 agonists; authors urge proactive counseling since the cosmetic effect can compromise adherence.
3. 03Paradoxical improvements in androgenetic and scarring alopecias were also reported; this is a narrative PubMed review, and pharmacovigilance signals were described as inconsistent.

From the source

GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?

Acta diabetologica · 2026 Oct 14 · Leite Júnior AC, Ribeiro Junior HL et al.